TargetBeta
TLR7
toll like receptor 7 · Toll like receptors
6 programs in company-led studies act on TLR7, from 6 companies: 3 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| resiquimodrule | Staidson (Beijing) Biopharmaceuticals | phase 3 | 144 running | TLR8 | NCIt |
| enpatoranrule | Merck KGaA, Darmstadt, Germany | phase 3 | 124 running | TLR8 | ChEMBL |
| afimetoranrule | Bristol-Myers Squibb | phase 3 | 122 running | TLR8 | ChEMBL |
| TLR7 Agonist JNJ-64794964 | Sino Biopharmaceutical | phase 2 | 61 running | – | the company's pipeline |
| Cholesteryl Pullulan Nanoparticle-formulated TLR7/8 Agonist UI-102rule | United Immunity | phase 2 | 11 running | – | NCIt |
| PRTX007rule | Primmune Therapeutics | phase 2 | 11 running | – | the studies' text |
Also acted on by the same programs
Conditions their studies are in
- COVID-19, 2 programs
- Lupus Erythematosus, Cutaneous, 2 programs
- Lupus Erythematosus, Systemic, 2 programs
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Dermatomyositis, 1 program
- Hepatitis B, 1 program
- Hepatitis B, Chronic, 1 program
- Hidradenitis Suppurativa, 1 program
- Melanoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026resiquimod · Staidson (Beijing) Biopharmaceuticals · phase 3 · NCT06246110
- Dec 2027PRTX007 · Primmune Therapeutics · phase 2 · NCT07565285
- Aug 12, 2028enpatoran · Merck KGaA, Darmstadt, Germany · phase 3 · NCT05540327
- Mar 31, 2030Cholesteryl Pullulan Nanoparticle-formulated TLR7/8 Agonist UI-102 · United Immunity · phase 2 · NCT07605962
- Apr 2030afimetoran · Bristol-Myers Squibb · phase 3 · NCT07881120
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.